Form 8-K

Date: June 19, 2013

REGENERON PHARMACEUTICALS, INC.

/s/ Joseph J. LaRosa

Joseph J. LaRosa

Senior Vice President, General Counsel,

and Secretary

0001193125-13-264466.txt : 20130620 0001193125-13-264466.hdr.sgml : 20130620 20130619174201 ACCESSION NUMBER: 0001193125-13-264466 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130614 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20130620 DATE AS OF CHANGE: 20130619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 13922855 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 8-K 1 d556139d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2013 (June 14, 2013)

REGENERON PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

New York

000-19034

13-3444607

(State or other jurisdiction

of Incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

(Address of principal executive offices, including zip code)

(914) 847-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07

Submission of Matters to a Vote of Security Holders.

At the 2013 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (the “Company”) held on June 14, 2013 (the “Annual Meeting”), the Company’s shareholders voted on the matters set forth below.

Proposal 1 – Election of Directors

The following nominees for Class I directors were elected to serve until the 2016 Annual Meeting of Shareholders and until a successor is duly elected based upon the following votes:


Nominee	Votes For		Votes Withheld		Broker Non-Votes
Michael S. Brown, M.D.		96,400,590		9,685,395		4,804,761
Leonard S. Schleifer, M.D., Ph.D.		96,505,521		9,580,464		4,804,761
Eric M. Shooter, Ph.D.		96,318,070		9,767,915		4,804,761
George D. Yancopoulos, M.D., Ph.D.		96,501,848		9,584,137		4,804,761

Proposal 2 – Ratification of Selection of Independent Registered Public Accountants

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013 was approved based upon the following votes:


For:			110,360,765
Against:			480,541
Abstain:			49,440

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.